ES2748590T3 - Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis - Google Patents
Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis Download PDFInfo
- Publication number
- ES2748590T3 ES2748590T3 ES12806846T ES12806846T ES2748590T3 ES 2748590 T3 ES2748590 T3 ES 2748590T3 ES 12806846 T ES12806846 T ES 12806846T ES 12806846 T ES12806846 T ES 12806846T ES 2748590 T3 ES2748590 T3 ES 2748590T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- cancer
- group
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*[n](c(*)c1*)c(N=CN2*)c1C2=N Chemical compound C*[n](c(*)c1*)c(N=CN2*)c1C2=N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576780P | 2011-12-16 | 2011-12-16 | |
| PCT/US2012/070155 WO2013090912A1 (en) | 2011-12-16 | 2012-12-17 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2748590T3 true ES2748590T3 (es) | 2020-03-17 |
Family
ID=47436279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12806846T Active ES2748590T3 (es) | 2011-12-16 | 2012-12-17 | Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9663521B2 (enExample) |
| EP (1) | EP2791142B1 (enExample) |
| JP (2) | JP6463130B2 (enExample) |
| AU (2) | AU2012353651B2 (enExample) |
| CA (1) | CA2859370C (enExample) |
| ES (1) | ES2748590T3 (enExample) |
| WO (1) | WO2013090912A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748590T3 (es) * | 2011-12-16 | 2020-03-17 | Us Health | Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis |
| CR20170076A (es) * | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| US9877966B1 (en) * | 2015-08-10 | 2018-01-30 | Eugene J. Oliva | Combination therapy for the inhibition of metastasis and tumorigenesis |
| WO2018140630A1 (en) * | 2017-01-25 | 2018-08-02 | Northwestern University | Autophagy inducers for treatment of cns conditions |
| US20210186972A1 (en) * | 2018-05-15 | 2021-06-24 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| AU2020408107B2 (en) | 2019-12-20 | 2026-04-23 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2024026064A1 (en) * | 2022-07-29 | 2024-02-01 | The University Of North Carolina At Chapel Hill | Enhancing antimetastasis activity using targeted protein degradation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES |
| EP2190466A4 (en) | 2007-08-10 | 2011-12-21 | Burnham Inst Medical Research | Tissue-specific alkaline phosphatase (TNAP) activators and their use |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2451278A2 (en) * | 2009-07-10 | 2012-05-16 | Microbiotix, Inc. | Inhibitors of filovirus entry into host cells |
| ES2748590T3 (es) * | 2011-12-16 | 2020-03-17 | Us Health | Compuestos y métodos para la prevención y el tratamiento de metástasis tumoral y tumorigénesis |
| JP6681070B2 (ja) * | 2015-11-19 | 2020-04-15 | 国立大学法人 岡山大学 | 光ファイバ装置及びセンサシステム |
-
2012
- 2012-12-17 ES ES12806846T patent/ES2748590T3/es active Active
- 2012-12-17 EP EP12806846.7A patent/EP2791142B1/en active Active
- 2012-12-17 JP JP2014547550A patent/JP6463130B2/ja active Active
- 2012-12-17 US US14/364,759 patent/US9663521B2/en active Active
- 2012-12-17 AU AU2012353651A patent/AU2012353651B2/en active Active
- 2012-12-17 WO PCT/US2012/070155 patent/WO2013090912A1/en not_active Ceased
- 2012-12-17 CA CA2859370A patent/CA2859370C/en active Active
-
2017
- 2017-05-23 JP JP2017102107A patent/JP6726640B2/ja active Active
- 2017-05-26 US US15/606,740 patent/US10301314B2/en active Active
- 2017-12-13 AU AU2017276258A patent/AU2017276258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9663521B2 (en) | 2017-05-30 |
| AU2012353651A1 (en) | 2014-07-10 |
| EP2791142B1 (en) | 2019-07-03 |
| JP6726640B2 (ja) | 2020-07-22 |
| US20140323438A1 (en) | 2014-10-30 |
| JP2017200921A (ja) | 2017-11-09 |
| JP6463130B2 (ja) | 2019-01-30 |
| EP2791142A1 (en) | 2014-10-22 |
| AU2017276258A1 (en) | 2018-01-18 |
| AU2012353651B2 (en) | 2017-09-14 |
| US10301314B2 (en) | 2019-05-28 |
| WO2013090912A1 (en) | 2013-06-20 |
| JP2015502367A (ja) | 2015-01-22 |
| CA2859370C (en) | 2021-01-26 |
| CA2859370A1 (en) | 2013-06-20 |
| US20170260192A1 (en) | 2017-09-14 |
| AU2017276258B2 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2791142B1 (en) | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | |
| JP7168773B2 (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
| ES2620634T3 (es) | Activadores de piruvato quinasa humana | |
| ES2577514T3 (es) | Antagonistas de TLR | |
| ES2906785T3 (es) | Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones | |
| ES2942308T3 (es) | Compuestos y su uso como inhibidores de BACE1 | |
| EP2938610A2 (en) | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof | |
| AU2016272057A1 (en) | Use of pteridinone derivative serving as EGFR inhibitor | |
| EP3070089A1 (en) | N-benzyl tryptanthrin derivative, and preparation method and application thereof | |
| ES2751642T3 (es) | Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer | |
| CN103204822A (zh) | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 | |
| ES2820553T3 (es) | Compuesto y composición farmacéutica para trastorno neuropsicológico o tumor maligno | |
| CN107835811A (zh) | 苯胺嘧啶衍生物及其用途 | |
| WO2013043192A1 (en) | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders | |
| CA3135755A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| ES2782357T3 (es) | Inhibidores de IRE 1 alfa | |
| ZA200609055B (en) | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics and anticancer agents | |
| ES2609459T3 (es) | Compuestos heterocíclicos condensados y su uso | |
| JP2012500249A (ja) | エピポドフィロトキシンの新規な（ポリ）アミノアルキルアミノアルキルアミド、アルキル−尿素またはアルキル−スルホンアミド誘導体、それらの製造方法、および治療における抗癌剤としてのそれらの応用 | |
| CN115703738B (zh) | 含2-芳杂环取代的脲类化合物、其制备方法和用途 | |
| US20140206645A1 (en) | Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase | |
| US9877966B1 (en) | Combination therapy for the inhibition of metastasis and tumorigenesis | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| CN107382967B (zh) | 咔唑磺酰胺衍生物或其可药用盐及其制备方法和应用 | |
| ES2994690T3 (en) | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |